588702-80-1

Basic information

• Product Name: Methyl2,3-Dihydro-benzofuran-5-carboxylate
• Synonyms: Methyl2,3-Dihydro-benzofuran-5-carboxylate;5-Benzofurancarboxylic acid, 2,3-dihydro-, Methyl ester;Methyl 2,3-dihydrobenzo[b]furan-5-carboxylate;2,3-Dihydro-5-benzofurancarboxylic acid Methyl ester
• CAS NO: 588702-80-1
• Molecular Formula: C₁₀H₁₀O₃
• Molecular Weight: 177.17666
• Mol File: 588702-80-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 296.2±19.0 °C(Predicted)
• Appearance: /
• Density: 1.208±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl2,3-Dihydro-benzofuran-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl2,3-Dihydro-benzofuran-5-carboxylate(588702-80-1)
• EPA Substance Registry System: Methyl2,3-Dihydro-benzofuran-5-carboxylate(588702-80-1)

Safety Data

• Hazardous Substances Data: 588702-80-1(Hazardous Substances Data)

Usage

General Description

Methyl 2,3-dihydro-benzofuran-5-carboxylate is a chemical compound with the molecular formula C11H12O3. It is an ester derivative of benzofuran, which is a heterocyclic compound containing a fused benzene and furan ring system. Methyl2,3-Dihydro-benzofuran-5-carboxylate is commonly used as a building block in the synthesis of various organic compounds, pharmaceuticals, and agrochemicals. It has also been studied for its potential biological activities, including its antioxidant and antitumor properties. Methyl 2,3-dihydro-benzofuran-5-carboxylate is a valuable chemical intermediate and plays an important role in the field of organic synthesis.

Upstream product

• 67-56-1 methanol 
• 76429-73-7 2,3-dihydrobenzofuran-5-carboxylic acid 
• 55745-70-5 2,3-dihydro-benzofuran-5-carbaldehyde 
• 108763-47-9 5-(methoxycarbonyl)benzo[b]furan 
• 42113-13-3 methyl 4-hydroxy-3-methylbenzoate 
• 90843-31-5 1-(2,3-dihydrobenzofuran-5-yl)ethanone 

Downstream Products

• 321195-99-7 2,3-dihydro-1-benzofuran-5-carbohydrazide 
• 90721-27-0 benzofuran-5-carboxylic acid 
• 108763-47-9 5-(methoxycarbonyl)benzo[b]furan 

Relevant articles and documents

Selective Hydrogenation of Benzofurans Using Ruthenium Nanoparticles in Lewis Acid-Modified Ruthenium-Supported Ionic Liquid Phases

Ruthenium nanoparticles immobilized on a Lewis-acid-functionalized supported ionic liquid phase (Ru?SILP-LA) act as effective catalysts for the selective hydrogenation of benzofuran derivatives to dihydrobenzofurans. The individual components (nanoparticles, chlorozincate-based Lewis-acid, ionic liquid, support) of the catalytic system are assembled using a molecular approach to bring metal and acid sites in close contact on the support material, allowing the hydrogenation of O-containing heteroaromatic rings while keeping the aromaticity of C6-rings intact. The chlorozincate species were identified to be predominantly [ZnCl4]2- anions using X-ray photoelectron spectroscopy and are in close interaction with the metal nanoparticles. The Ru?SILP-[ZnCl4]2- catalyst exhibited high activity, selectivity, and stability for the catalytic hydrogenation of a variety of substituted benzofurans, providing easy access to biologically relevant dihydrobenzofuran motifs under continuous flow conditions.

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.

Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β

Glycogen synthase kinase-3β (GSK-3β) is implicated in abnormal hyperphosphorylation of tau protein and its inhibitors are expected to be a promising therapeutic agents for the treatment of Alzheimer's disease. Here we report design, synthesis and structure-activity relationships of a novel series of oxadiazole derivatives as GSK-3β inhibitors. Among these inhibitors, compound 20x showed highly selective and potent GSK-3β inhibitory activity in vitro and its binding mode was determined by obtaining the X-ray co-crystal structure of 20x and GSK-3β.